Evaluating the Utility of 18F-FDG PET/CT in Cancer of Unknown Primary
- Author(s)
- Sivakumaran, T; Cardin, A; Callahan, J; Wong, HL; Tothill, RW; Hicks, RJ; Mileshkin, LR;
- Details
- Publication Year 2024-10-01,Volume 65,Issue #10,Page 1557-1563
- Journal Title
- Journal of Nuclear Medicine
- Publication Type
- Research article
- Abstract
- Cancer of unknown primary (CUP) represents a heterogeneous group of metastatic tumors for which standardized diagnostic work-up fails to identify the primary site. We aimed to describe the Peter MacCallum Cancer Centre experience with (18)F-FDG PET/CT in extracervical CUP with respect to detection of a primary site and its impact on management. A secondary aim was to compare overall survival (OS) in patients with and without a detected primary site. Methods: CUP patients treated between 2014 and 2020 were identified from medical oncology clinics and (18)F-FDG PET/CT records. Information collated from electronic medical records included the suspected primary site and treatment details before and after (18)F-FDG PET/CT. Clinicopathologic details and genomic analysis were used to determine the clinically suspected primary site and compared against 2 independent masked reads of (18)F-FDG PET/CT images by nuclear medicine specialists to determine sensitivity, specificity, accuracy, and the rate of detection of the primary site. Results: We identified 147 patients, 65% of whom had undergone molecular profiling. The median age at diagnosis was 61 y (range, 20-84 y), and the median follow-up time was 74 mo (range, 26-83 mo). Eighty-two percent were classified as having an unfavorable CUP subtype as per international guidelines.(18)F-FDG PET/CT demonstrated a primary site detection rate of 41%, resulted in a change in management in 22%, and identified previously occult disease sites in 37%. Median OS was 16.8 mo for all patients and 104.7 and 12.1 mo for favorable and unfavorable CUP subtypes, respectively (P < 0.0001). Median OS in CUP patients when using (18)F-FDG PET/CT, clinicopathologic, and genomic information was 19.8 and 8.5 mo when a primary site was detected and not detected, respectively (P = 0.016). Multivariable analysis of survival adjusted for age and sex remained significant for identification of a potential primary site (P < 0.001), a favorable CUP (P < 0.001), and an Eastern Cooperative Oncology Group status of 1 or less (P < 0.001). Conclusion: (18)F-FDG PET/CT plays a complementary role in CUP diagnostic work-up and was able to determine the likely primary site in 41% of cases. OS is improved with primary site identification, demonstrating the value of access to diagnostic (18)F-FDG PET/CT for CUP patients.
- Publisher
- Society of Nuclear Medicine and Molecular Imaging
- Keywords
- Humans; *Positron Emission Tomography Computed Tomography; *Fluorodeoxyglucose F18; *Neoplasms, Unknown Primary/diagnostic imaging; Male; Female; Middle Aged; Aged; Adult; Aged, 80 and over; Young Adult; Retrospective Studies; 18f-fdg pet/ct; carcinoma of unknown primary; overall survival
- Department(s)
- Medical Oncology; Cancer Imaging
- Publisher's Version
- https://doi.org/10.2967/jnumed.123.267274
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-11-07 06:54:38
Last Modified: 2024-11-07 06:54:57